Cyera Is a Proud Participant in the Microsoft Sentinel Partner Ecosystem

Cyera today announced its inclusion in the Microsoft Sentinel partner ecosystem. Cyera was selected based on their proven ...

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled ...